rosiglitazone has been researched along with Shock in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caputi, AP; Chatterjee, PK; Cuzzocrea, E; Cuzzocrea, S; Di Paola, R; Di Rosa, M; Dugo, L; Fulia, F; Genovese, T; Ianaro, A; Patel, NS; Pisano, B; Thiemermann, C | 1 |
1 other study(ies) available for rosiglitazone and Shock
| Article | Year |
|---|---|
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice.
Topics: Animals; Lipid Peroxidation; Male; Mice; Multiple Organ Failure; Nitric Oxide; Nitrosation; Rosiglitazone; Shock; Thiazolidinediones; Zymosan | 2004 |